Octapharma’s balanced portfolio built on a very special juice
The Journal of Haemophilia Practice · 2013
DOI: 10.17225/jhp.00023 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Haemophilia Practice, 2013. Verfasst von Kate Khair. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair
Zitieren
APA
Khair, K. (2013). Octapharma’s balanced portfolio built on a very special juice. The Journal of Haemophilia Practice. https://doi.org/10.17225/jhp.00023
Vancouver
Khair K. Octapharma’s balanced portfolio built on a very special juice. The Journal of Haemophilia Practice. 2013. doi:10.17225/jhp.00023
BibTeX
@article{Khair2013,
author = {Khair, Kate},
title = {Octapharma’s balanced portfolio built on a very special juice},
journal = {The Journal of Haemophilia Practice},
year = {2013},
doi = {10.17225/jhp.00023}
}
EUVIMED